Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.62 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.62 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.62 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.62 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6354991 | 1.00 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4040247 | 0.91 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5864611 | 0.91 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4052132 | 0.90 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14181942 | 0.90 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14263762 | 0.88 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14592061 | 0.85 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14079226 | 0.85 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4375328 | 0.85 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14263742 | 0.85 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503998-B1 | HETEROARYL SUBSTITUTED SPIROCYCLIC SUFAMIDES FOR INHIBITION OF GAMMA SECRETASE | MERCK SHARP & DOHME (GB) | 2009-07-01 | — | — | EP | disclosed |
| US-20080070895-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | COLLINS IAN J | 2008-03-20 | — | — | US | disclosed |
| US-20080070895-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | COLLINS IAN J | 2008-03-20 | — | — | US | disclosed |
| US-7282513-B2 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-16 | — | — | US | disclosed |
| US-7282513-B2 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-16 | — | — | US | disclosed |
| US-20060173054-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-08-03 | — | — | US | disclosed |
| US-7041689-B2 | Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME LTD. (GB) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173054-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 5/4885APH1B 8/4885 |
| US-20080070895-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 5/4885APH1B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.